AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30455177 — intervention group
Group type: EXPERIMENTAL
Intervention: Partition display nudge (low-value options presented horizontally, high-value options listed vertically)
Number of subjects: 120
Study 29121282 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 49
Study 29121282 — intervention group
Group type: COMPARATOR
Intervention: Plasma-Lyte 148® (PL)
Number of subjects: 49
Study 26123384 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 50
Study 26123384 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Number of subjects: 50
Study 23761484 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation (400 mg DHA daily)
Number of subjects: 261
Study 23761484 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation
Number of subjects: 261
Study 22279783 — intervention group
Group type: EXPERIMENTAL
Intervention: Selzink medicine, a one-month course of therapy
Number of subjects: 0
Study 19193572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered face-to-face group program (3 sessions)
Number of subjects: 101
Study 19193572 — intervention group
Group type: COMPARATOR
Intervention: Standard care telephone session (5-10 minutes)
Number of subjects: 101
Study 16796760 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional CD-ROM education (E)
Number of subjects: 230
Study 16796760 — intervention group
Group type: COMPARATOR
Intervention: Standard information (S)
Number of subjects: 230
Study 12771602 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day group
Number of subjects: 258
Study 12771602 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day group
Number of subjects: 258
Study 11097668 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mL (6 mg) of plain 0.5% bupivacaine (group 1; n = 30)
Number of subjects: 60
Study 11097668 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mL (6 mg) of hyperbaric 0.5% bupivacaine in 8% glucose (group 2; n = 30)
Number of subjects: 60
Study 8638546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA)
Number of subjects: 100
Study 8638546 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy of 5-FU and HDFA plus low-dose alpha-2b interferon
Number of subjects: 100
Study 1317694 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (loading dose, 400 mg or 500 mg followed by 200 mg or 500 mg three times daily for 5 days)
Number of subjects: 87
Study 1317694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 6543609 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2.5 mg/kg)
Number of subjects: 0
Study 6543609 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/kg)
Number of subjects: 0
Study 6543609 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 29280866 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA injected in the lateral eyebrow depressors alone (group 1)
Number of subjects: 15
Study 29280866 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA injected in both the lateral and medial eyebrow depressors (group 2)
Number of subjects: 15
Study 29280866 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group 1 and group 2
Number of subjects: 15
Study 29280866 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 15
Study 27460602 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss dietary interventions (four diets varying in macronutrient intakes)
Number of subjects: 811
Study 24571869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage (IBS) in group I
Number of subjects: 50
Study 24571869 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 50
Study 21732418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=79)
Number of subjects: 160
Study 21732418 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=81)
Number of subjects: 160
Study 19950398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Cytology (FNAC) for benign neoplastic lesions
Number of subjects: 100
Study 19950398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Cytology (FNAC) for malignant neoplastic lesions
Number of subjects: 100
Study 19950398 — intervention group
Group type: COMPARATOR
Intervention: Biopsy (control)
Number of subjects: 100
Study 17385973 — intervention group
Group type: EXPERIMENTAL
Intervention: FV intervention group
Number of subjects: 20
Study 17385973 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions
Number of subjects: 20
Study 17385973 — intervention group
Group type: EXPERIMENTAL
Intervention: Trying more recipes
Number of subjects: 20
Study 15855257 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (n = 25, approximately 20 microg/kg.d)
Number of subjects: 58
Study 15855257 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (n = 25)
Number of subjects: 58
Study 15855257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 58
Study 15855257 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 18)
Number of subjects: 58
Study 12021220 — intervention group
Group type: EXPERIMENTAL
Intervention: X-sizer thrombectomy system
Number of subjects: 66
Study 12021220 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI alone
Number of subjects: 66
Study 10464128 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (40 mg/kg loading dose followed by 2 mg/kg oral for 16 weeks)
Number of subjects: 96
Study 10464128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 10464128 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (azathioprine and placebo)
Number of subjects: 96
Study 9248904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular sumatriptan 6 mg
Number of subjects: 43
Study 9248904 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chlorpromazine, 12.5 mg increments to a maximum of 37.5 mg
Number of subjects: 43
Study 1911008 — intervention group
Group type: COMPARATOR
Intervention: Continuous i.m. infusion of ketorolac 10 mg
Number of subjects: 0
Study 1911008 — intervention group
Group type: COMPARATOR
Intervention: Intermittent i.m. injection of ketorolac 10 mg administered 4-hourly
Number of subjects: 0
Study 1911008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7139397 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of succinylcholine (self-taming)
Number of subjects: 60
Study 7139397 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine 0.04 mg/kg
Number of subjects: 60
Study 7139397 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (control group)
Number of subjects: 60
Study 30897391 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Trauma (CT) - Sexual Abuse
Number of subjects: 82
Study 30897391 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Trauma (CT) - Physical Neglect
Number of subjects: 82
Study 30897391 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Trauma (CT) - High CT
Number of subjects: 82
Study 30897391 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Trauma (CT) - Physical Neglect and Depression
Number of subjects: 82
Study 28612893 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitute tear + mixture (Bifidobacterium lactis and Bifidobacterium bifido)
Number of subjects: 40
Study 28612893 — intervention group
Group type: COMPARATOR
Intervention: Substitute tear (control)
Number of subjects: 40
Study 26189209 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008
Study 26189209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study 26189209 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 1008
Study 26189209 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1008
Study 25001440 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka honey with UMF 19.5
Number of subjects: 0
Study 25001440 — intervention group
Group type: COMPARATOR
Intervention: Regular tooth brushing regimen
Number of subjects: 0
Study 22193575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Number of subjects: 94
Study 22193575 — intervention group
Group type: COMPARATOR
Intervention: Minimal smoking cessation intervention
Number of subjects: 94
Study 20616673 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐E2 (1 mg/d for 1 mo, then 2 mg/d for 2 mo)
Number of subjects: 22
Study 20616673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 17873238 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 12
Study 17873238 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg
Number of subjects: 12
Study 17873238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16140224 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10mg daily
Number of subjects: 20
Study 16140224 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 16140224 — intervention group
Group type: COMPARATOR
Intervention: screening
Number of subjects: 20
Study 16140224 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine
Number of subjects: 20
Study 11859907 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 3500
Study 10402678 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract predicates used as prompts
Number of subjects: 5
Study 10402678 — intervention group
Group type: COMPARATOR
Intervention: Concrete predicates used as prompts
Number of subjects: 5
Study 10402678 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between memory and preferential predicate use
Number of subjects: 5
Study 7599565 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-MTX
Number of subjects: 29
Study 7599565 — intervention group
Group type: COMPARATOR
Intervention: CsA-MTX-MP
Number of subjects: 29
Study 2384206 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder issued to patients in the experimental group during the middle year
Number of subjects: 1175
Study 2384206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminder issued)
Number of subjects: 1175
Study 6104498 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 5 mg
Number of subjects: 6
Study 6104498 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg
Number of subjects: 6
Study 6104498 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg
Number of subjects: 6
Study 6104498 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg
Number of subjects: 6
Study 6104498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31426018 — intervention group
Group type: COMPARATOR
Intervention: Deceptive placebo
Number of subjects: 154
Study 31426018 — intervention group
Group type: COMPARATOR
Intervention: Open-label placebo
Number of subjects: 154
Study 31426018 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 154
Study 28064251 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary vein access
Number of subjects: 74
Study 28064251 — intervention group
Group type: COMPARATOR
Intervention: Cephalic vein access
Number of subjects: 74
Study 25986292 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity pamphlet
Number of subjects: 80
Study 25986292 — intervention group
Group type: COMPARATOR
Intervention: Stress management pamphlet
Number of subjects: 80
Study 23434769 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-ups (4 calls at 7 days, 1 month, 6 months, and 9 months)
Number of subjects: 300
Study 23434769 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (control group)
Number of subjects: 300
Study 20845391 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of melatonin every night for 14 days or until discharge
Number of subjects: 145
Study 20845391 — intervention group
Group type: COMPARATOR
Intervention: Placebo every night for 14 days or until discharge
Number of subjects: 145
Study 19438696 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protocol
Number of subjects: 100
Study 19438696 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dobutamine
Number of subjects: 100
Study 19438696 — intervention group
Group type: COMPARATOR
Intervention: Infra-low-dose dipyridamole
Number of subjects: 100
Study 17657857 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (n=30)
Number of subjects: 60
Study 17657857 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion (n=30)
Number of subjects: 60
Study 15851822 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive training over 24 weeks
Number of subjects: 16
Study 15851822 — intervention group
Group type: COMPARATOR
Intervention: Control group (CN)
Number of subjects: 16
Study 11216718 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 279
Study 11216718 — intervention group
Group type: COMPARATOR
Intervention: Preoperative demand levels (low vs medium/high)
Number of subjects: 279
Study 11216718 — intervention group
Group type: COMPARATOR
Intervention: Demand matching hypothesis
Number of subjects: 279
Study 9919901 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT-175 (40-160 mg/day) administered during the initial 4 days following surgery
Number of subjects: 34
Study 9919901 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-FUT group) with 455 patients treated without FUT-175
Number of subjects: 34
Study 9919901 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY-046 as part of standard care
Number of subjects: 34
Study 8116990 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic patients with cardiomyopathy (Group A)
Number of subjects: 101
Study 1976298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral astemizole for 8 weeks
Number of subjects: 51
Study 1976298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 26139 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 6
Study 26139 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 6
Study 31758576 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06480605 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 800 mg IV (SAD)
Number of subjects: 92
Study 31758576 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06480605 3 × 500 mg IV, or 3 × 30 mg, 3 × 100 mg, or 3 × 300 mg SC every 2 weeks for three doses (MAD)
Number of subjects: 92
Study 31758576 — intervention group
Group type: COMPARATOR
Intervention: PF-06480605 (SAD and MAD)
Number of subjects: 92
Study 31758576 — intervention group
Group type: COMPARATOR
Intervention: PF-06480605 vs placebo cohorts
Number of subjects: 92
Study 31156217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampasse (5, 10, or 25 mg intravenously once a day for 15 days)
Number of subjects: 80
Study 31156217 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (placebo)
Number of subjects: 80
Study 28076709 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate (7.4 GBq every 8 weeks, plus best supportive care including octreotide LAR 30 mg IM)
Number of subjects: 229
Study 28076709 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR (60 mg IM every 4 weeks)
Number of subjects: 229
Study 28076709 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate
Number of subjects: 229
Study 28076709 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 229
Study 25891440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 680
Study 25891440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg/day
Number of subjects: 680
Study 25891440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study 23818488 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine applied to the laryngeal surface
Number of subjects: 54
Study 23818488 — intervention group
Group type: COMPARATOR
Intervention: Saline aerosol
Number of subjects: 54
Study 21368459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 0
Study 19135496 — intervention group
Group type: EXPERIMENTAL
Intervention: SC599 vaccine 10^5 CFU
Number of subjects: 111
Study 19135496 — intervention group
Group type: EXPERIMENTAL
Intervention: SC599 vaccine 10^7 CFU
Number of subjects: 111
Study 19135496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 19135496 — intervention group
Group type: EXPERIMENTAL
Intervention: SC599 vaccine
Number of subjects: 111
Study 17920547 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-specific therapy targeting myelin proteins
Number of subjects: 0
Study 17920547 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length myelin basic protein or key peptide epitope (residues 83-99)
Number of subjects: 0
Study 15239532 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily chest physiotherapy
Number of subjects: 32
Study 15239532 — intervention group
Group type: COMPARATOR
Intervention: Control (no chest physiotherapy)
Number of subjects: 32
Study 12575568 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese and Western medicine (TCM-WM) for over 10 months
Number of subjects: 106
Study 12575568 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 106
Study 12575568 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory and analgesic agents
Number of subjects: 106
Study 12575568 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese and Western medicine (TCM-WM)
Number of subjects: 106
Study 9591935 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice with 10 mg felodipine ER
Number of subjects: 12
Study 9591935 — intervention group
Group type: COMPARATOR
Intervention: Control (water with 10 mg felodipine ER)
Number of subjects: 12
Study 7869288 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser
Number of subjects: 0
Study 7869288 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 0
Study 2533057 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol daily
Number of subjects: 26
Study 2533057 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg celiprolol daily
Number of subjects: 26
Study 2533057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31268476 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 159
Study 31268476 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg
Number of subjects: 159
Study 31268476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 29137506 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled Cash Transfer (LCT)
Number of subjects: 0
Study 29137506 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled Cash Transfer with Commitment (L-CCT)
Number of subjects: 0
Study 24618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosurgery system (VERSAJET)
Number of subjects: 40
Study 24618054 — intervention group
Group type: COMPARATOR
Intervention: Conventional debridement
Number of subjects: 40
Study 23265698 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut SLIT
Number of subjects: 40
Study 23265698 — intervention group
Group type: COMPARATOR
Intervention: Crossover subjects receiving peanut SLIT
Number of subjects: 40
Study 23265698 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut doses through the Week 44 OFCs
Number of subjects: 40
Study 21593252 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 92
Study 21593252 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 92
Study 21593252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 18845032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar diathermy
Number of subjects: 105
Study 18845032 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia then pack compression
Number of subjects: 105
Study 18845032 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression of the tonsillar fossae with gauze packs
Number of subjects: 105
Study 18845032 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-stained saliva presence
Number of subjects: 105
Study 16478899 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d of rimonabant
Number of subjects: 3045
Study 16478899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3045
Study 15246619 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine (two doses at 2 and 4 months of age)
Number of subjects: 192
Study 15246619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses at 2 and 4 months of age)
Number of subjects: 192
Study 11252647 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 14
Study 11252647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 14
Study 9088653 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray 50 micrograms twice/daily (Group 1)
Number of subjects: 38
Study 9088653 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 10.4 mg three times/day (Group 2)
Number of subjects: 38
Study 9088653 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 3)
Number of subjects: 38
Study 8223830 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 44
Study 8223830 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 44
Study 8223830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 44
Study 3011180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine ointment
Number of subjects: 103
Study 3011180 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone ointment
Number of subjects: 103
Study 3011180 — intervention group
Group type: COMPARATOR
Intervention: Warm sitz baths plus bran
Number of subjects: 103